Komori
Share Issuance and Disposal4883Modalis Therapeutics CorporationPharmaceuticals

Notice of Completion of Payment for the 2nd Unsecured Corporate Bond (Private Placement)

Payment totaling ¥270 million for the 2nd unsecured corporate bonds, for which EVO FUND is the subscriber, has been completed.

Worth reading
60In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
270000000
¥
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of 2nd unsecured straight bonds (private placement bonds)

Intended allottee
EVO FUND
Total issue value

¥270,000,000

Amount of funds to be raised
Total amount paid: ¥270,000,000; estimated net proceeds: Not disclosed
Payment date
26 June 2026
Most recent equity financing
19th Series Stock Acquisition Rights issued on 12 June 2026 (as described in this document)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of 2nd unsecured straight bonds (private placement bonds)
Issue price and disposal price¥100 per ¥100 of face value
Total issue value¥270,000,000
Amount of funds to be raisedTotal amount paid: ¥270,000,000; estimated net proceeds: Not disclosed
Payment date26 June 2026
Intended allotteeEVO FUND
Most recent equity financing19th Series Stock Acquisition Rights issued on 12 June 2026 (as described in this document)
Items this document does not state (21)
Number of shares to be issued or disposed ofEstimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodNumber of Stock Acquisition RightsTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Payment for the corporate bonds approved on 27 May 2026 has been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for the 2nd Unsecured Corporate Bond (Private Placement) | Modalis Therapeutics Corporation (4883) timely disclosure | Komori